Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

NCT05239169 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer (CCA)
Intrahepatic Cholangiocarcinoma
Hilar Cholangiocarcinoma
Distal Cholangiocarcinoma
Gall Bladder Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Capecitabine

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest